Loculated Empyema and SARS-CoV-2 Infection: A Report of Two Cases and Review of the Literature.

Autor:	Ayad S; Internal Medicine, Rutgers-New Jersey Medical School/Trinitas Regional Medical Center, Elizabeth, New Jersey, USA., Gergis K; Internal Medicine, McLaren Health Care, Flint, Michigan, USA., Elkattawy S; Internal Medicine, Rutgers-New Jersey Medical School/Trinitas Regional Medical Center, Elizabeth, New Jersey, USA., Mirza N; St. George's University, Grenada, West Indies., Abdelazeem B; Internal Medicine, McLaren Health Care, Flint, Michigan, USA., Patel L; Internal Medicine, Rutgers-New Jersey Medical School/Trinitas Regional Medical Center, Elizabeth, New Jersey, USA., Remolina C; Department of Pulmonology, Trinitas Regional Medical Center, Elizabeth, New Jersey, USA.
Jazyk:	angličtina
Zdroj:	European journal of case reports in internal medicine [Eur J Case Rep Intern Med] 2021 Jul 15; Vol. 8 (7), pp. 002706. Date of Electronic Publication: 2021 Jul 15 (Print Publication: 2021).
DOI:	10.12890/2021_002706
Abstrakt:	Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical manifestations are diverse and can vary from mild respiratory symptoms to severe hypoxic respiratory failure. In severe cases, infection can cause gastrointestinal, renal, cardiac, neurological and haematological complications and result in multi-organ failure. There are very few reports of parapneumonic effusion in patients with COVID-19. We describe two patients with COVID-19 who had loculated empyema and discuss the clinical course and therapeutic options. Learning Points: The clinical manifestations of COVID-19 vary from mild to severe disease and can result in multi-organ failure.Pleural empyema is usually treated with a combination of antibiotics and surgical drainage of the pleural cavity. Competing Interests: Conflict of interests: The authors declare there are no competing interests. (© EFIM 2021.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu